BPC-157 Research Overview: Published Studies & Mechanism Profile
Published: 2026-03-07Updated: 2026-03-10Category: Peptide Profiles
BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide derived from human gastric juice protein. With over 100 preclinical publications, it has the most extensive research base of any non-FDA-approved peptide. This overview summarizes the published science.
Basic Profile
| Property | Value |
|---|
| Sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Amino Acids | 15 |
| Molecular Weight | 1419.53 Da |
| CAS Number | 137525-51-0 |
| Origin | Fragment of human gastric juice protein BPC |
| FDA Status | Category 2 (Sep 2023) — not approved for any use |
| Published Studies | 100+ preclinical (primarily from University of Zagreb) |
Mechanism of Action (Published Research)
In preclinical studies, BPC-157 has been observed to upregulate growth factor receptor expression (VEGF, FGF, EGF), modulate the nitric oxide (NO) system (both NOS-dependent and independent pathways), influence the FAK-paxillin signaling pathway involved in cell migration and adhesion, and interact with the dopaminergic and serotonergic systems in CNS models.
Unlike most peptides that are studied in a single organ system, BPC-157's research spans GI, musculoskeletal, cardiovascular, and neurological models — making it one of the most broadly studied compounds in preclinical peptide research.
Key Published Findings
GI tract: The original and most extensive research area. Published studies observed cytoprotective effects in multiple ulcer models, inflammatory bowel disease models, and NSAID-induced damage models. Oral bioavailability via PepT1 transporter uptake was studied in animal models.
Musculoskeletal: Observed accelerated tendon-to-bone remodeling in rat models. Observed effects on muscle fiber repair and ligament biology. A 2024 systematic review summarized musculoskeletal study outcomes across multiple tissue types.
Cardiovascular: Observed post-MI cardiac tissue remodeling. Observed angiogenic activity in published models.
CNS: Observed modulation of dopaminergic pathways. Studied in models of NSAID-induced CNS effects and ethanol-related neurotoxicity models.
Important Research Context
Critical note: As of February 2026, 35 of 36 published BPC-157 studies originate from a single laboratory (University of Zagreb), and a STAT News investigation noted undisclosed conflicts. No large-scale randomized controlled trials in humans have been published. The extensive preclinical data has not been validated in independent human studies.
Research Availability
BPC-157 is available as a research chemical reference material at Pepta Labs in multiple dosages. Third-party COA included. See our BPC-157 vs TB-500 comparison for context on related cytoprotective compounds.
All information is sourced from published peer-reviewed literature and provided for educational purposes only. This content does not represent claims about products sold by Pepta Labs. All products are chemical reference materials for in-vitro laboratory research only. Not for human or animal consumption. See
Terms of Service and
Compliance Policy.
Browse Research Compounds
34+ peptides. Third-party COAs. Free US shipping.
View Catalog →